Trials / Unknown
UnknownNCT05333276
Clinical Trial of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers
A Phase I Study of the TQB3602 Capsule Combined With AK105 Injection in Patients With Advanced Cancers
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
TQB3602 is a kind of proteasome inhibitor, AK105 is an anti-programmed cell death protein 1 (PD-1) antibody.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3602 Capsule + AK105 Injection | TQB3602 is a kind of proteasome inhibitor, AK105 is an anti-PD-1 antibody. |
Timeline
- Start date
- 2022-07-29
- Primary completion
- 2023-12-01
- Completion
- 2024-05-01
- First posted
- 2022-04-18
- Last updated
- 2023-07-27
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05333276. Inclusion in this directory is not an endorsement.